Lymphocyte activation gene 3 served as a potential prognostic and immunological biomarker across various cancer types: a clinical and pan‐cancer analysis
Clinical & Translational Immunology · 2024-01 · 13 (10)
DOI: 10.1002/cti2.70009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 04.10.2024. Verfasst von Yifan Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Rising-Star Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
Lymphocyte activation gene 3 (LAG3), an inhibitory receptor in T‐cell activation, is a negative prognostic factor. However, its impact on tumours has yet to be comprehensively elucidated on a pan‐cancer scale. Thus, we aim to reveal its role at the pan‐cancer level.
Methods
We performed IHC staining on a retrospective cohort of 370 patients. Then we assessed the prognostic effect of LAG3 using Kaplan–Meier survival analysis and multivariate Cox regression analysis. In pan‐cancer analysis, we constructed competing endogenous RNA and protein–protein interaction networks, conducted gene set enrichment analysis and identified correlations between LAG3 gene expression and various factors, including clinical characteristics, tumour purity, mutations, tumour immunity and drug sensitivity across 33 cancer types.
Results
LAG3 was expressed higher in normal kidney tissues than in tumours. A high level of LAG3 gene expression was an independent prognostic factor for OS (HR = 6.60, 95% CI = 2.43–17.90, P < 0.001) and PFS (HR = 3.44, 95% CI = 1.68–7.10, P < 0.001). In pan‐cancer analysis, LAG3 exhibited robust correlations with survival and tumour stages in various cancers. Moreover, LAG3 was strongly associated with immune‐related genes, proteins and signalling pathways. LAG3 gene expression was positively associated with increased infiltration of activated immune cells and decreased infiltration of several resting cells. LAG3 gene expression was associated with tumour mutation burden and microsatellite instability in multiple cancers.
Conclusion
High LAG3 gene expression was an independent risk factor in kidney neoplasms. It also functioned as a biomarker for prognosis, TIME and immunotherapy efficacy in the pan‐cancer dimension.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
- Department of Pathology Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
- Department of Burn Surgery The First Affiliated Hospital of Naval Medical University Shanghai China.
Förderung
- Shanghai Rising-Star Program
- National Natural Science Foundation of China
Zitieren
APA
Liu, Y., Yao, Y., Yang, X., Wei, M., Lu, B., Dong, K., Lyu, D., Li, Y., Guan, W., Huang, R., Xu, G., & Pan, X. (2024). Lymphocyte activation gene 3 served as a potential prognostic and immunological biomarker across various cancer types: a clinical and pan‐cancer analysis. Clinical & Translational Immunology, 13(10). https://doi.org/10.1002/cti2.70009
Vancouver
Liu Y, Yao Y, Yang X, Wei M, Lu B, Dong K, et al. Lymphocyte activation gene 3 served as a potential prognostic and immunological biomarker across various cancer types: a clinical and pan‐cancer analysis. Clinical & Translational Immunology. 2024;13(10). doi:10.1002/cti2.70009
BibTeX
@article{Liu2024,
author = {Liu, Yifan and Yao, Yuntao and Yang, Xinyue and Wei, Maodong and Lu, Bingnan and Dong, Keqing and Lyu, Donghao and Li, Yuanan and Guan, Wenbin and Huang, Runzhi and Xu, Guofeng and Pan, Xiuwu},
title = {Lymphocyte activation gene 3 served as a potential prognostic and immunological biomarker across various cancer types: a clinical and pan‐cancer analysis},
journal = {Clinical & Translational Immunology},
year = {2024},
volume = {13},
number = {10},
doi = {10.1002/cti2.70009}
}
EUVIMED